Incidence of oral lesions in HIV-1-infected women: Reduction with HAART

Journal of Dental Research

Volumn 83, Issue 2, 2004, Pages 145-150

  Greenspan, D ^a   Gange, S J ^b   Phelan, J A ^c   Navazesh, M ^d   Alves, M E A F ^e   MacPhail, L A ^f   Mulligan, R ^d   Greenspan, J S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f TEMPLE UNIVERSITY   (United States)

Author keywords

HAART; Hairy leukoplakia; HIV; Oral candidiasis; Women

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPLAKIA; MOUTH DISEASE; MULTICENTER STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK; THRUSH; VERRUCA VULGARIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; LEUKOPLAKIA, HAIRY; MOUTH DISEASES; ODDS RATIO; PROSPECTIVE STUDIES; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; WARTS;

EID: 4143088049     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910408300212     Document Type: Article

References (30)

1. Ahdieh L, Gange SJ, Greenblatt R, Minkoff H, Anastos K, Young M, et al. (2000). Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol 152:923-933.
2. Anastos K, Barron Y, Miotti P, Weiser B, Young M, Hessol N, et al. (2002). Risk of progression to AIDS and death in women infected with HIV-I initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med 162:1973-1980.
3. Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia JJ, Pena JM, Gonzalez A, Canedo T, et al. (2000). Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 14:979-985.
4. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. (1998). The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 9:117-125.
5. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. (2000). Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 283:381-390.
6. Cauda R, Tacconelli E, Tumbarello M, Morace G, De Bernardis F, Torosantucci A, et al. (1999). Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr Hum Retrovirol 21:20-25.
7. Cook JA, Cohen MH, Grey D, Kirstein L, Burke J, Anastos K, et al (2002). Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health 92:82-87.
8. Dios PD, Ocampo A, Miralles C, Limeres J, Tomas I (2000). Changing prevalence of human immunodeficiency virus-associated oral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90:403-404.
9. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus (1993). Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 22:289-291.
10. Gange SJ, Barron Y, Greenblatt RM, Anastos K, Minkoff H, Young M, et al. (2002). Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health 56:153-159.
11. Greenspan D, Komaroff E, Redford M, Phelan JA, Navazesh M, Alves ME, et al. (2000). Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 25:44-50.
12. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS (2001). Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 357:1411-1412.
13. Greenspan JS, Greenspan D (2002). The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 8(Suppl 2):34-39.
14. Greenspan JS, Barr CE, Sciubba JJ, Winkler JR, USA Oral AIDS Collaborative Group (1992). Oral manifestations of HIV infection: definitions, diagnostic criteria and principles of therapy. Oral Surg Oral Med Oral Pathol 73:142-144.
15. Greenwood I, Zakrzewska JM, Robinson PG (2002). Changes in the prevalence of HIV-associated mucosal disease at a dedicated clinic over 7 years. Oral Dis 8:90-94.
16. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM (2002). Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 34:641-648.
17. Leigh IM, Buchanan JA, Harwood CA, Cerio R, Storey A (1999). Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. J Acquir Immune Defic Syndr 1:S49-S57.
18. Levine AM (2002). Evaluation and management of HIV-infected women. Ann Intern Med 136:228-242.
19. MacPhail LA, Komaroff E, Alves ME, Navazesh M, Phelan JA, Redford M (2002). Differences in risk factors among clinical types of oral candidiasis in the Women's Interagency HIV Study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93:45-55.
20. Margiotta V, Campisi G, Mancuso S, Accurso V, Abbadessa V (1999). HIV infection: oral lesions, CD4+ cell count and viral load in an Italian study population. J Oral Pathol Med 28:173-177.
21. Mulligan R, Navazesh M, Komaroff E, Greenspan D, Redford M, Alves M, et al. (2000). Salivary gland disease in human immunodeficiency virus-positive women from the WIHS study. Women's Interagency HIV Study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:702-709.
22. Navazesh M, Mulligan R, Komaroff E, Redford M, Greenspan D, Phelan J (2000). The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women. J Dent Res 79:1502-1507.
23. Palacio H, Hilton JF, Canchola AJ, Greenspan D (1997). Effect of cigarette smoking on HIV-related oral lesions. J Acquir Immune Defic Syndr Hum Retrovirol 14:338-342.
24. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Bonner U, Jay N, et al. (2001). Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 28:422-428.
25. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
26. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr (2000). Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:299-304.
27. Porter SR, Scully C (1998). HIV topic update: protease inhibitor therapy and oral health care. Oral Dis 4:159-163.
28. Shiboski CH (2002). HIV-related oral disease epidemiology among women: year 2000 update. Oral Dis 8(Suppl 2):44-48.
29. Shiboski CH, Neuhaus JM, Greenspan D, Greenspan JS (1999). Effect of receptive oral sex and smoking on the incidence of hairy leukoplakia in HIV-positive gay men. J Acquir Immune Defic Syndr 21:236-242.
30. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. (2002). Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 288:222-235.